Clinical Trials
5 trialsNCT03162536 2025-09-08
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Active not recruiting
NCT06644443 2024-10-16
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Shenzhen University General Hospital
Phase 1/2 Recruiting
NCT01183949 2024-08-02
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01063907 2024-04-25
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT01435720 2014-09-11
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Senesco Technologies, Inc.
Phase 1/2 Unknown